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GUEST COMMENTARY
In Vitro Susceptibility Testing of Haemophilus influenzae:
Review of New National Committee for Clinical
Laboratory Standards Recommendations
GARY V. DOERN
Division of Clinical Microbiology, Department of Hospital Laboratories, University of
Massachusetts Medical Center, Worcester, Massachusetts 01655
In June 1987, the Antimicrobial Susceptibility Testing
Subcommittee of the National Committee for Clinical Lab-
oratory Standards (NCCLS) established a fastidious-organ-
ism working group expressly for the purpose of addressing
issues related to in vitro susceptibility tests with aerobic or
microaerophilic bacteria that do not grow well on unsupple-
mented Mueller-Hinton (MH) media. The fastidious-organ-
ism working group considered Haemophilus influenzae, for
which no standardized method of susceptibility testing was
available, for either disk diffusion or dilution susceptibility
testing. Previously, numerous media with various inoculum
sizes and conditions of incubation had been employed (24).
Clearly, medium composition is crucial to susceptibility test
results with Haemophilus spp. (1, 4-6, 17). Perhaps the most
widely used medium for disk testing ofH. influenzae, at least
in the United States, has been chocolatized MH agar (MH-
choc) (25). Indeed, the NCCLS had promulgated zone
diameter interpretive criteria for four antimicrobial agents,
ampicillin, amoxicillin-clavulanate, ampicillin-sulbactam,
and chloramphenicol, when H. influenzae is tested on MH-
choc (21). Similarly, the broth medium, MH supplemented
with lysed horse blood (3 to 5%) (MH-LHB), appeared to be
used more commonly than other media for dilution tests with
this organism (25). MIC interpretive criteria existed for the
same four antimicrobial agents (20).
The first issue considered by the NCCLS was the optimum
medium composition for susceptibility tests with Haemo-
philus spp. Concerns pertaining to MH-choc included its
opacity, its undefined chemical composition, and its lack of
utility for trimethoprim-sulfamethoxazole (TMP-SMX) disk
diffusion tests due to the presence of large amounts of
thymidine and thymidine analogs. The major shortcomings
of MH-LHB broth for dilution tests with Haemophilus spp.
were its lack of commercial availability and the logistical
complexities of preparing this medium in house. For these
reasons, the NCCLS considered alternative media for stan-
dardized disk diffusion and dilution susceptibility tests with
Haemophilus spp.
In January 1988, the use of Haemophilus Test Medium
(HTM), a new medium first developed by Jorgensen and
colleagues (16), was explored. The agar form of HTM
consisted of MH agar, 15 ,ug of hematin per ml, 15 jig of
NAD per ml, and 5 ,ug of yeast extract per ml. The broth
version of HTM consisted of cation-adjusted MH broth, 0.2
IU of thymidine phosphorylase per ml, and the same sup-
plements used in HTM agar. In preliminary studies with 15
antimicrobial agents, laboratory-prepared agar and broth
versions of HTM were stable and appeared to support the
growth of fresh clinical isolates of H. influenzae (16, 17).
Other presumed advantages of HTM were its transparent
nature, its ability to support disk diffusion tests with TMP-
SMX, its lack of expense, and its chemical composition,
which was more defined than that of MH-choc; in addition,
HTM permitted the use of the same basal medium in both
disk diffusion and broth dilution tests, and the broth version
of the medium could be manufactured commercially.
On the basis of a series of preliminary studies (23a), the
NCCLS adopted HTM as the recommended medium for disk
diffusion and dilution susceptibility testing of Haemophilus
spp. in January 1988 (22, 23). In addition, methods for both
procedures were described. With disk diffusion tests, HTM
plates should be incubated at 35°C in CO2 (5 to 7%) for 16 to
18 h prior to zones of inhibition being read. Inocula are to be
prepared from a saline suspension of the test organism
equivalent in turbidity to a 0.5 McFarland standard. Because
of the importance of accurate inoculum concentrations, it
was recommended that this initial suspension be prepared
with a bench-top nephelometric device directly from colony
growth on a 20- to 24-h chocolate agar culture. The method
chosen for dilution tests with HTM was a broth microdilu-
tion procedure (final volume per well, 100 pl) with trays
incubated for 24 h at 35°C in ambient air and a final inoculum
concentration of 5 x 105 CFU/ml.
Using HTM and these methods, a three-center collabora-
tive study was conducted to develop interpretive criteria for
disk diffusion and broth microdilution results (9). On the
basis of the results of this study, interpretive criteria for 18
antimicrobial agents tested against Haemophilus spp. were
adopted in June 1988 by the NCCLS (22, 23). These antimi-
crobial agents included ampicillin, amoxicillin-clavulanate,
ampicillin-sulbactam, cefuroxime, cefamandole, cefonicid,
cefaclor, ceftriaxone, cefotaxime, ceftizoxime, ceftazidime,
imipenem, aztreonam, chloramphenicol, tetracycline, TMP-
SMX, rifampin, and ciprofloxacin. In June 1989, interpretive
criteria for cefixime were adopted, as were quality control
(QC) criteria for the antimicrobial agents, which now num-
bered 19 (22, 23). These QC criteria had been developed in a
six-center collaborative study using a non-typeable P-lacta-
mase-negative, ampicillin-resistant (BLNAR) strain of H.
influenzae, ATCC 49247, as a challenge organism (7). This
strain was selected because it yielded adequate inter- and
intralaboratory precision in the controlled, six-center collab-
orative study. It grew well on HTM and yielded zone sizes,
and the MICs of most antimicrobial agents for this strain
were midrange because of its BLNAR characteristics.
During the past 2 1/2 years, the NCCLS has adopted
3035
 at UNIV O
F M
ASS M
ED SCH on July 15, 2008 
jcm.asm.org
D
ow
nloaded from
 
3036 GUEST COMMENTARY
interpretive criteria for HTM disk diffusion and broth micro-
dilution tests with seven additional antimicrobial agents:
loracarbef, cefprozil, cefetamet, ofloxacin, lomefloxacin,
azithromycin, and clarithromycin. QC criteria have been
adopted for all of these agents, plus the following nine
others: cefmetazole, cefpirome, cefepime, cefdinir, cefpo-
doxime, ceftibuten, meropenem, trospectomycin, and fle-
roxacin. Although not yet specifically addressed by the
NCCLS, the results of one study suggest that the media,
methods, and interpretive criteria described above for H.
influenzae are also applicable to other species of Haemo-
philus (8).
As might be expected with changes as extensive as those
undertaken with Haemophilus susceptibility tests, several
problems have arisen. In 1990 and early 1991, it became
apparent that laboratories performing disk diffusion suscep-
tibility tests with H. influenzae with HTM agar and 30-p,g
cefixime disks were reporting disproportionately large num-
bers of resistant strains (llb). Reanalysis of the results of the
initial collaborative study for cefixime interpretive criteria
indicated that a 30-pg disk had been used, whereas a 5-,g
disk was common in clinical practice. As a result, a second
study with 5-,g cefixime disks was performed to establish
new cefixime zone diameter interpretive criteria (4a). The
results of this study led to a revision of the disk diffusion
interpretive criteria for cefixime in June 1991.
Questions concerning the adequacy of the zone diameter
interpretive criteria that had been established for cefaclor
with HTM and 30-p,g disks have also been raised (24b).
Specifically, it was contended that the initial NCCLS zone
diameter criteria of .18 (resistant [R]) and .24 (S) were too
conservative and would result in too many strains of H.
influenzae being categorized as falsely resistant or interme-
diate. Zone diameter frequency distribution data from one
laboratory indicated that the use of the initial criteria would
result in a combined cefaclor resistance and intermediate
rate of approximately 25% (24a). Rates of resistance of this
magnitude seemed inconsistent with the apparent therapeu-
tic efficacy of cefaclor. Therefore, in June 1992, on the basis
of the results of a six-center collaborative study (lla) aimed
at reassessing zone diameter interpretive criteria for rela-
tively ,B-lactamase-labile cephalosporins such as cefaclor,
the NCCLS modified the cefaclor disk diffusion interpretive
criteria to .16 (R) and .20 (S). Provisional cefprozil and
loracarbef zone diameter interpretive criteria were also
changed, to .14 (R) and .18 (S) for cefprozil and c15 (R)
and .19 (S) for loracarbef.
Ampicillin was used as an internal control agent in the
six-center collaborative study noted above. Interestingly,
the results of this study indicated that the ampicillin zone
diameter interpretive criteria initially adopted in 1988 also
needed to be revised. In June 1992, the following zone
diameter criteria were adopted for HTM ampicillin disk
diffusion tests: .18 (R) and .22 (S). This change is consis-
tent with the observations of one recent investigation (11).
Among 87 BLNAR clinical isolates of H. influenzae, 13
(15%) yielded ampicillin zone diameters of .24 mm on
HTM, i.e., they would have been falsely categorized as
resistant or intermediate. The new interpretive criteria
would have correctly categorized the large majority of these
13 strains as susceptible.
Another issue concerns HTM QC testing. Initially, QC
ranges of 4 to 5 mm were adopted for most antimicrobial
agents when they were tested against ATCC 49247. While
these ranges had been developed by using statistical analysis
similar to that for non-fastidious organism-antimicrobial
agent combinations, in practice they proved too narrow. As
a result, QC ranges for HTM disk diffusion tests with ATCC
49247 were adjusted so that, in most cases, the range became
8 to 9 mm. Also, inconsistent QC results were noted with
HTM agar when the antimicrobial agents cefaclor, cefurox-
ime, cefamandole, and cefonicid were tested against ATCC
49247. An observation that the MH base used to prepare
HTM agar had a profound effect on disk diffusion results
with these antimicrobial agents and ATCC 49247 was made
(3, llc). For these reasons, a study was done to identify an
alternative strain for HTM disk diffusion QC tests with
cefaclor, cefuroxime, cefamandole, cefonicid, and loracar-
bef (12). On the basis of the results of this study in June 1991,
the NCCLS replaced ATCC 49247 with ATCC 49766 as the
recommended QC strain for disk diffusion tests with ce-
faclor, cefuroxime, cefamandole, cefonicid, and loracarbef
(23). In June 1992, QC criteria based on ATCC 49766 were
also adopted for cefprozil. Although there was no evidence
that MIC QC tests with ATCC 49247 were problematic, a
second study was conducted in an effort to develop QC
ranges for MIC tests with cefaclor, cefuroxime, cefaman-
dole, cefonicid, and loracarbef against ATCC 49247 (2). The
results of this study were also adopted by the NCCLS.
The consequence of these changes is that it is now easier
to obtain "in-control" values with disk diffusion and possi-
bly broth microdilution QC tests with the six antimicrobial
agents noted in the previous paragraph. With the adoption of
ATCC 49766, media-related problems that would have been
observed with ATCC 49247 disappear. The question of
which control strain yields the most valid results arises.
Unfortunately, there currently exists no definitive answer to
this important question. Clearly, however, the NCCLS has
judged that ATCC 49247 provided too rigorous a test for
cefaclor, cefuroxime, cefamandole, cefonicid, cefprozil, and
loracarbef on HTM.
A variety of other concerns pertain to current NCCLS
recommendations for Haemophilus susceptibility tests with
HTM. With numerous antimicrobial agents, e.g., broad-
spectrum cephalosporins, imipenem, aztreonam, and the
fluoroquinolones, few or no clearly resistant strains exist for
testing. As a result, the use of frequency distribution analy-
sis to define interpretive criteria for results, as has been done
by the NCCLS, may be questioned. Because of a lack of
resistant strains, the NCCLS has appropriately elected to
define only a susceptible category for these agents; however,
even this conservative approach has problems. First, it has
been suggested that in vitro testing of antimicrobial agents
should be directed toward identifying resistant rather than
susceptible strains. If so, a test that defines only susceptible
organisms is of little value. Second, how are breakpoints
best established for a unimodal susceptible population, close
to the population or at some distance from the population? In
the first case, the test is best able to detect organisms only
slightly more resistant than the unimodal population, but it
would also tend to overestimate resistance. In the second
case, resistant strains might not be as easily detected;
however, the problem of false resistance would be dimin-
ished. With regard to this problem, the NCCLS has adopted
the following approach: the zone diameter breakpoint for the
susceptible category is established at 6 mm smaller than the
highest zone size capturing 99% of the unimodal population.
The MIC breakpoint is established at 2 dilutions lower than
the MIC for 90% of the strains of the unimodal population
tested.
Several unresolved problems with HTM remain. Exten-
sive anecdotal experience indicates frequent episodes of
J. CLIN. MICROBIOL.
 at UNIV O
F M
ASS M
ED SCH on July 15, 2008 
jcm.asm.org
D
ow
nloaded from
 
GUEST COMMENTARY 3037
poor growth or actual growth failures with HTM. Two
published studies have alluded to this problem (1, 11). By
contrast, the six-center study cited above, which was con-
ducted with the intent of reassessing zone diameter interpre-
tive criteria with antimicrobial agents such as cefaclor and
cefprozil, did not experience major problems with growth
failures. Inadequate growth on HTM, when it does occur, is
probably due to the X-factor constituent of the medium,
which is supplied in the form of purified hematin. Hematin is
poorly soluble and extremely unstable. Some clinical iso-
lates of H. influenzae may have very high X-factor growth
requirements. Such strains are characterized by narrow
zones of growth surrounding X- or V-factor-impregnated
strips in satellitism tests. These strains may fail to grow on or
in HTM if it has been prepared inadequately or if it has been
stored for various periods of time. Recognizing this problem,
in January 1990, the NCCLS officially adopted a recommen-
dation that manufacturers of HTM routinely test production
lots with H. influenzae ATCC 10211. This strain has a high
X-factor growth requirement. A manufacturer's use of
ATCC 10211 does not, of course, address the problem of
poor shelf life. Therefore, individual laboratories might also
employ ATCC 10211 as a growth control.
A further difficulty pertains to inter- and intramanufac-
turer variability with batches of HTM (2, 7, 11, 12). Such
variability is perhaps not surprising, as the individual ingre-
dients used to make HTM have profound effects on media
performance. Problems related to manufacturing have
prompted at least one national commercial media vendor to
decline to offer HTM. Among those vendors selling HTM,
Becton Dickinson Microbiology Systems (Cockeysville,
Md.) has the most experience making and distributing this
medium.
In addition to lot-to-lot variability, within-lot variability
also exists with HTM-based susceptibility tests (2, 7, 12).
The magnitude of this problem is unknown. It has been only
casually addressed in the literature (1) and currently remains
largely unexplained.
A third problem concerns testing BLNAR strains of H.
influenzae. All such strains should be considered resistant to
ampicillin, amoxicillin-clavulanate, ampicillin-sulbactam,
and the relatively 3-lactamase-labile cephalosporins, such as
cefaclor, cefuroxime, cefonicid, cefamandole, cefprozil, and
the new carbacephem, loracarbef (14, 18). A fairly convinc-
ing argument may be made for the assertion that it is
detection of these strains that is the primary objective -of in
vitro susceptibility testing with Haemophilus spp. Excepting
TMP-SMX and perhaps tetracycline, other antimicrobial
agents are either predictably active or inactive, or they are
best assessed by enzyme tests, such as ,B-lactamase or
chloramphenicol acetyltransferase assays (9, 13). Unfortu-
nately, current NCCLS HTM-based methods and interpre-
tive criteria may not effectively identify BLNAR strains as
ampicillin resistant (10, 19) or, for that matter, as resistant to
the eight antimicrobial agents listed above (4a). First of all,
technical problems often occur when BLNAR strains of H.
influenzae are tested against beta-lactam antimicrobial
agents with HTM. These include indistinct zones of inhibi-
tion and in growth with disk diffusion tests and trailing
endpoints with broth microdilution tests. The recommended
inoculum size of 5 x 105 CFU/ml may be a contributing
factor with MIC tests. MH base appears to significantly
influence the expression of the activities of cephalosporins
such as cefaclor and cefuroxime against BLNAR strains (3,
llc). These technical problems are further complicated by
the following observations. If resistance is defined according
to MICs, then disk diffusion tests with certain beta-lactam
antimicrobial agents on HTM do not adequately separate
BLNAR strains of H. influenzae from strains which are
susceptible. Establishing zone diameter breakpoints with
compounds such as cefaclor so as to appropriately catego-
rize BLNAR strains as cefaclor resistant would lead to a
disproportionate number of susceptible strains being catego-
rized as intermediate or, in a few cases, resistant. The same
problem applies with cefprozil, loracarbef, and, to some
extent, ampicillin, P-lactamase inhibitor combinations, cef-
uroxime, cefonicid, cefamandole, and perhaps cefixime.
As stated previously, one question arises: what is the
objective of in vitro susceptibility tests, to detect resistance
or to detect susceptibility? After much deliberation, the
NCCLS decided to establish zone diameter interpretive
criteria with these agents in such a way that susceptible
strains would be correctly categorized as susceptible. As a
consequence, BLNAR strains will commonly be falsely
categorized as susceptible. This decision was predicated on
commercial interests and on the observation that BLNAR
strains currently remain distinctly uncommon in the United
States. It may have to be reconsidered in the future.
In conclusion, the NCCLS has recently adopted a new
approach to susceptibility testing of H. influenzae. While
this approach appears to represent progress in the area of
susceptibility testing of this fastidious bacterium, several
problems have been identified, and these remain to be
resolved. The obvious question is, what should laboratories
do today when confronted with clinical isolates of Haemo-
philus spp.? One possibility is to not perform susceptibility
tests at all. A strong case can be made for performing only a
P-lactamase assay and possibly a test for chloramphenicol
acetyltransferase, at least with the large majority of clinical
isolates in the United States (8). When susceptibility tests
with specific antimicrobial agents are judged necessary,
one of two approaches can be taken. Employ the current
NCCLS-recommended methods with HTM, excercising
caution in ensuring that the medium used performs satisfac-
torily and that test results are in control. If for any reason an
alternative method is deemed necessary, disk diffusion tests
may be performed with MH-choc plates and disks containing
ampicillin, chloramphenicol, amoxicillin-clavulanate, and
ampicillin-sulbactam. Interpretive criteria are those orig-
inally published by the NCCLS for MH-choc (21). MICs of
any agent may be determined with MH-LHB-10 p,g of NAD
per ml. A broth microdilution format with a 100-,u final
volume, an inoculum concentration of 5 x 10 CFU/ml, and
trays incubated for 20 to 24 h at 35°C in ambient air should be
employed. The major limitation of disk diffusion tests with
MH-choc plates and MICs with MH-LHB is the lack of
published QC criteria. It may be, however, that laboratories
that have traditionally used these media in the past have
developed their own internal QC standards. Finally, it is
clear that much more needs to be learned before any single
method can be advocated with complete assurance for all
Haemophilus susceptibility tests.
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